oxytetracycline--anhydrous and Vaginitis

Eighty-one patients with clinical diagnosis of aerobic vaginitis (AV) were included in the study. The patients were randomized for treatment, 45 with kanamycin (100 mg vaginal ovules for 6 days, consecutively) and 36 with meclocycline (35 mg vaginal ovules for 6 days, consecutively). The patients were examined before starting the study, 1-2 days after treatment and 30 days after the end of the study. At the first follow-up the patients showed different levels of symptom reduction. Reduction in the presence of leukocytes, vaginal mucosa burning and itching were statistically significant in the group treated with kanamycin with respect to the group treated with meclocycline. Moreover, there was also reduced isolation of Enterobacteriaeae (97%) in the group treated with kanamycin versus those treated with meclocycline (76%). At the second follow-up, vaginal homeostasis (normalization of pH and presence of lactobacilli) was more evident in the kanamycin-treated group. In conclusion, our data suggest that the topical use of kanamycin could be considered a specific antibiotic for the therapy of this new pathology.

Topics: Administration, Topical; Adult; Anti-Bacterial Agents; Bacteria, Aerobic; Female; Humans; Kanamycin; Lactobacillus; Oxytetracycline; Vaginitis

In a study of the diagnosis and treatment of Corynebacterium vaginale (Haemophilus vaginalis) vaginitis in 30 patients, clinical and microscopical findings were compared with laboratory cultures. The study also included a double-blind randomised trial of treatment regimens including placebo therapy. Laboratory cultures of C. vaginale corresponded well with clinical findings, and we suggest that C. vaginale vaginitis can be reliably diagnosed with clinical and microscopical findings. Tetracycline was effective in half the patients treated, whereas all but 1 of the 17 patients eventually treated with metronidazole were cured. The apparent discrepancy between in-vitro sensitivity and in-vitro efficacy of metronidazole in this condition is discussed.

Topics: Adolescent; Adult; Clinical Trials as Topic; Double-Blind Method; Drug Resistance, Microbial; Female; Gardnerella vaginalis; Haemophilus Infections; Humans; Metronidazole; Oxytetracycline; Vaginitis

This study aimed to correlate the inflammatory reaction (IR) caused by a progesterone-releasing intravaginal device (P4) with ovarian activity and pregnancy rate (PR) in embryo-recipient anestrus mares (to decrease the spring transitional period). 50 animals were assigned to three groups: GP4 (P4 group; n = 16), GP4OH (P4 + oxytetracycline hydrochloride and hydrocortisone sprayed onto the device; n = 14), and GNP4 (no intravaginal P4; n = 20). The administration protocol for GP4 was: Day 0, 750 mg P4 + ovarian examination by ultrasonography (US) + vaginal sample collection; Day 8, US; Day 11, P4 removal + 7.5 mg PGF2α + US + second vaginal sample collection; Days 13 to 16, US; Days 17 to 21, US + 750 IU hCG to mares with follicles 35 mm or more in diameter; Days 19 to 23 US (ovulation check); Days 24 to 28, embryo transfer + intravenous flunixin meglumine; and Days 30, US pregnancy diagnosis. The GP4OH and GNP4 mares received the same administration protocol as GP4, except that no P4 device was administered to the GNP4 group on Day 0. Although neutrophil-mediated IR occurred in the GP4 and GP4OH groups, the IR was significantly reduced in GP4OH as compared with that in GP4 (P < 0.0001). From Day 0 to Day 17, the GP4 and GP4OH mares developed a greater number of follicles per animal than did the GNP4 mares (P < 0.05), and the average diameter of the follicles was larger in the GP4 and GP4OH mares. The ovulation rates in GP4, GP4OH, and GNP4 mares were, respectively, 43.7%, 64.3%, and 30.0%, and ovulation occurred at 6.8, 6.5, and 23 days after P4 removal (P < 0.05). On Day 17, endometrial edema was verified in 50%, 64.2%, and 35.0% of the GP4, GP4OH, and GNP4 mares, and the PRs after embryo transfer were 80%, 100%, and 66.6%, respectively. Although intravaginal devices caused IR in both the device-recipient groups (P = 0.0001), IR and vaginitis had no negative impact on follicle diameter, ovulation rate, period to ovulation after the removal of P4, endometrial edema, or PR. In addition, P4 reactivated the ovarian function and the IR eliminated a large percentage of bacteria (Bacillus spp., Enterobacter spp., Proteus spp., Pseudomonas spp., and Staphylococcus spp.), especially in GP4; the application of oxytetracycline hydrochloride and hydrocortisone on the devices reduced the severity of vaginitis.

Topics: Administration, Intravaginal; Animals; Drug Implants; Embryo Transfer; Escherichia coli; Female; Horses; Hydrocortisone; Ovarian Follicle; Ovulation; Oxytetracycline; Pregnancy; Pregnancy Rate; Progesterone; Streptococcus; Vaginitis

A trial was performed in 30 patients affected by non-specific vaginitis. The results show that the topical application (by vaginal washings) of flunoxaprofen produces a high therapeutic activity like that of meclocycline. Contrary to meclocycline, flunoxaprofen does not possess bactericidal and bacteriostatic properties. Therefore, the normalization of vaginal flora, with a remarkable increase of Döderlein bacillus, is exclusively due to local antiphlogistic activity of flunoxaprofen. Contrary to meclocycline, flunoxaprofen induces a precocious increase of Döderlein bacillus, necessary for a definitive normalization and to limit the possibility of relapses.

Topics: Administration, Intravaginal; Adolescent; Adult; Anti-Infective Agents, Local; Anti-Inflammatory Agents, Non-Steroidal; Benzoxazoles; Female; Humans; Oxytetracycline; Vaginitis

Topics: Adult; Drug Evaluation; Female; Humans; Oxytetracycline; Suppositories; Vaginitis

Attention is drawn to the incidence of colpitis and the symptom of "vaginal discharge" in the gynaecological field, as well as to the required investigations as far as differential diagnosis is concerned. Severe, purulent, unspecific colpitis and also recurrent colpitis require particularly careful treatment. Excellent therapeutic results have been achieved over many years with repeated local administration of TC-Gel-Steraject and, if necessary, additional treatment with an oestriol preparation; this therapy is therefore recommended.

Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents; Drug Combinations; Estriol; Female; Humans; Hydrocortisone; Leukorrhea; Middle Aged; Oxytetracycline; Polymyxins; Vaginitis

Topics: Acute Disease; Adolescent; Adult; Aged; Female; Humans; Hydrocortisone; Middle Aged; Oxytetracycline; Time Factors; Vaginitis

Topics: Adolescent; Adult; Female; Humans; Imidazoles; Leukorrhea; Male; Nystatin; Oxytetracycline; Vaginitis

Topics: Female; Humans; Oxytetracycline; Pharmaceutic Aids; Trichomonas Vaginitis; Vaginitis

Topics: Adolescent; Adult; Aged; Candidiasis, Vulvovaginal; Female; Humans; Middle Aged; Oxytetracycline; Pregnancy; Pregnancy Complications, Infectious; Trichomonas Vaginitis; Vaginitis

Topics: Biomedical Research; Female; Humans; Infections; Neoplasms; Oxytetracycline; Radium; Uterine Neoplasms; Vaginitis

Topics: Anti-Bacterial Agents; Chloramphenicol; Chlortetracycline; Drug Resistance, Microbial; Female; Humans; Lactobacillus; Leukorrhea; Oxytetracycline; Vaginitis

Topics: Anti-Bacterial Agents; Female; Humans; Hydrocortisone; Intraabdominal Infections; Oxytetracycline; Trichomonas; Trichomonas Infections; Trichomonas Vaginitis; Uterine Cervicitis; Vaginitis

Topics: Female; Humans; Leukorrhea; Oxytetracycline; Suppositories; Trichomonas; Trichomonas Vaginitis; Vaginal Discharge; Vaginitis

Topics: Female; Humans; Intraabdominal Infections; Oxytetracycline; Pessaries; Trichomonas; Trichomonas Infections; Trichomonas Vaginitis; Vaginitis; Vulvovaginitis

Topics: Female; Humans; Intraabdominal Infections; Oxytetracycline; Trichomonas; Trichomonas Infections; Trichomonas Vaginitis; Vaginitis; Vulvovaginitis

Topics: Chlortetracycline; Female; Humans; Intraabdominal Infections; Leukorrhea; Oxytetracycline; Trichomonas; Trichomonas Infections; Trichomonas Vaginitis; Vaginitis; Vulvovaginitis

Topics: Disease; Female; Humans; Oxytetracycline; Trichomonas; Trichomonas Infections; Vagina; Vaginal Diseases; Vaginitis; Vulvovaginitis

Topics: Disease; Female; Humans; Oxytetracycline; Trichomonas Infections; Trichomonas vaginalis; Vagina; Vaginal Diseases; Vaginitis; Vulvovaginitis

Topics: Disease; Female; Humans; Oxytetracycline; Trichomonas Infections; Trichomonas vaginalis; Trichomonas Vaginitis; Vagina; Vaginal Diseases; Vaginitis

Topics: Disease; Female; Humans; Oxytetracycline; Trichomonas vaginalis; Trichomonas Vaginitis; Vagina; Vaginal Diseases; Vaginitis

Topics: Chlortetracycline; Disease; Female; Humans; Oxytetracycline; Trichomonas vaginalis; Vagina; Vaginal Diseases; Vaginitis; Vulvovaginitis